<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01365286</url>
  </required_header>
  <id_info>
    <org_study_id>Ivabradine2009-2011</org_study_id>
    <nct_id>NCT01365286</nct_id>
  </id_info>
  <brief_title>HR-lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease</brief_title>
  <official_title>Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Universtity of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Universtity of Lodz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate heart rate lowering efficacy and respiratory
      safety of ivabradine in patients with asthma and COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this double blind, placebo-controlled, crossover study, 20 asthmatics and 20 COPD patients
      received ivabradine 7,5 mg b.i.d. and placebo for 5 days in crossover manner. HR in ECG
      holter monitoring, peak expiratory flow rate (PEFR), symptoms, rescue medication consumption
      and AEs were evaluated in both periods of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Change from baseline in heart rate during 5-day ivabradine and 5-day placebo treatment (24-hour ECG monitoring on the 3rd day)</time_frame>
    <description>Difference in mean heart rate during ivabradine and placebo treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak expiratory flow rate (PEFR)</measure>
    <time_frame>Everyday measurement of morning and evening PEFR during 5-day ivabradine and 5-day placebo treatment</time_frame>
    <description>Difference in mean daily PEFR during ivabradine and placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>Everyday symptom scoring during 5 day ivabradine and 5-day placebo treatment</time_frame>
    <description>Difference in mean daily symptom score between ivabradine and placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication</measure>
    <time_frame>Everyday rescue medication usage assessments during 5-day ivabradine and 5-day placebo treatment</time_frame>
    <description>Difference in mean daily rescue medication use between ivabradine and placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Number of patients with AEs evaluated throughout the study (5-day ivabradine and 5 day placebo treatment)</time_frame>
    <description>Difference in number of participants with AEs between ivabradine and placebo treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Asthma, Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Ivabradine-Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Ivabradine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine (Procoralan)</intervention_name>
    <description>Ivabradine 7,5 mg b.i.d. for 5 days and Placebo b.i.d. for 5 days (Ivabradine-Placebo)</description>
    <arm_group_label>Ivabradine-Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)</description>
    <arm_group_label>Placebo-Ivabradine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  documented diagnosis of asthma or COPD in accordance with guidelines

          -  stable condition, defined as a disease without exacerbation for at least 1 month prior
             to study enrolment

          -  mean HR in holter ECG recording of â‰¥ 60 bpm

        Exclusion Criteria:

          -  disease exacerbation in previous month

          -  inability to understand instructions on study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Lodz, Department of Pneumonology and Allergy</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987 Jun;113(6):1489-94.</citation>
    <PMID>3591616</PMID>
  </reference>
  <reference>
    <citation>Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension. 1997 Nov;30(5):1267-73.</citation>
    <PMID>9369286</PMID>
  </reference>
  <reference>
    <citation>Hjalmarson A, Gilpin EA, Kjekshus J, Schieman G, Nicod P, Henning H, Ross J Jr. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol. 1990 Mar 1;65(9):547-53.</citation>
    <PMID>1968702</PMID>
  </reference>
  <reference>
    <citation>Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J. 1991 Jan;121(1 Pt 1):172-7.</citation>
    <PMID>1985358</PMID>
  </reference>
  <reference>
    <citation>Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M; Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007 Aug 28;50(9):823-30. Epub 2007 Aug 13. Review.</citation>
    <PMID>17719466</PMID>
  </reference>
  <reference>
    <citation>Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999 Jun 26;318(7200):1730-7.</citation>
    <PMID>10381708</PMID>
  </reference>
  <reference>
    <citation>Frishman WH, Furberg CD, Friedewald WT. The use of beta-adrenergic blocking drugs in patients with myocardial infarction. Curr Probl Cardiol. 1984 Jun;9(3):1-50. Review.</citation>
    <PMID>6146495</PMID>
  </reference>
  <reference>
    <citation>Gheorghiade M, Goldstein S. Beta-blockers in the post-myocardial infarction patient. Circulation. 2002 Jul 23;106(4):394-8.</citation>
    <PMID>12135934</PMID>
  </reference>
  <reference>
    <citation>Farrell MH, Foody JM, Krumholz HM. beta-Blockers in heart failure: clinical applications. JAMA. 2002 Feb 20;287(7):890-7.</citation>
    <PMID>11851583</PMID>
  </reference>
  <reference>
    <citation>Fihn SD, Williams SV, Daley J, Gibbons RJ; American College of Cardiology; American Heart Association; American College of Physicians-American Society of Internal Medicine. Guidelines for the management of patients with chronic stable angina: treatment. Ann Intern Med. 2001 Oct 16;135(8 Pt 1):616-32.</citation>
    <PMID>11601935</PMID>
  </reference>
  <reference>
    <citation>Benson MK, Berrill WT, Cruickshank JM, Sterling GS. A comparison of four beta-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol. 1978 May;5(5):415-9.</citation>
    <PMID>26371</PMID>
  </reference>
  <reference>
    <citation>Schwartz S, Davies S, Juers JA. Life-threatening cold and exercise-induced asthma potentiated by administration of propranolol. Chest. 1980 Jul;78(1):100-1.</citation>
    <PMID>7471827</PMID>
  </reference>
  <reference>
    <citation>Williams IP, Millard FJ. Severe asthma after inadvertent ingestion of oxprenolol. Thorax. 1980 Feb;35(2):160.</citation>
    <PMID>7376124</PMID>
  </reference>
  <reference>
    <citation>Chang CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J. 2010 Mar;40(3):193-200. doi: 10.1111/j.1445-5994.2009.01943.x. Epub 2009 Mar 10.</citation>
    <PMID>19383058</PMID>
  </reference>
  <reference>
    <citation>DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64(16):1757-65. Review.</citation>
    <PMID>15301560</PMID>
  </reference>
  <reference>
    <citation>Babu KS, Gadzik F, Holgate ST. Absence of respiratory effects with ivabradine in patients with asthma. Br J Clin Pharmacol. 2008 Jul;66(1):96-101. doi: 10.1111/j.1365-2125.2008.03160.x. Epub 2008 Mar 13.</citation>
    <PMID>18341671</PMID>
  </reference>
  <reference>
    <citation>Ageev FT, Makarova GV, Patrusheva IF, Orlova IaA. [The efficacy and safety of the combination of Î²-blocker bisoprolol and if inhibitor I(f) ivabradine in patients with stable angina and chronic obstructive pulmonary disease]. Kardiologiia. 2010;50(10):22-6. Russian.</citation>
    <PMID>21118175</PMID>
  </reference>
  <reference>
    <citation>Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004 May;59(5):469-78. Review.</citation>
    <PMID>15080825</PMID>
  </reference>
  <reference>
    <citation>Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986 Apr 25;57(12):43F-49F.</citation>
    <PMID>2871745</PMID>
  </reference>
  <reference>
    <citation>Lechat P. Beta-blocker treatment in heart failure. Role of heart rate reduction. Basic Res Cardiol. 1998;93 Suppl 1:148-55. Review.</citation>
    <PMID>9833143</PMID>
  </reference>
  <reference>
    <citation>Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006 Jun;27(11):1341-81. Epub 2006 May 30.</citation>
    <PMID>16735367</PMID>
  </reference>
  <reference>
    <citation>Ford ES, Giles WH, Croft JB. Prevalence of nonfatal coronary heart disease among American adults. Am Heart J. 2000 Mar;139(3):371-7.</citation>
    <PMID>10689247</PMID>
  </reference>
  <reference>
    <citation>Lipworth BJ, Irvine NA, McDevitt DG. The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol. Eur J Clin Pharmacol. 1991;40(5):467-71.</citation>
    <PMID>1653143</PMID>
  </reference>
  <reference>
    <citation>Lammers JW, Folgering HT, van Herwaarden CL. Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S69-73.</citation>
    <PMID>2439802</PMID>
  </reference>
  <reference>
    <citation>Roche N, Huchon G. [Epidemiology of chronic obstructive pulmonary disease]. Rev Prat. 2004 Sep 15;54(13):1408-13. Review. French.</citation>
    <PMID>15497793</PMID>
  </reference>
  <reference>
    <citation>Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, Pistelli R. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997 Dec;10(12):2794-800.</citation>
    <PMID>9493663</PMID>
  </reference>
  <reference>
    <citation>Cazzola M, Calzetta L, Bettoncelli G, Novelli L, Cricelli C, Rogliani P. Asthma and comorbid medical illness. Eur Respir J. 2011 Jul;38(1):42-9. doi: 10.1183/09031936.00140310. Epub 2010 Dec 22.</citation>
    <PMID>21177843</PMID>
  </reference>
  <reference>
    <citation>Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004 Jun;125(6):2309-21.</citation>
    <PMID>15189956</PMID>
  </reference>
  <reference>
    <citation>Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2002 Dec;110(6 Suppl):S322-8. Review.</citation>
    <PMID>12464943</PMID>
  </reference>
  <reference>
    <citation>Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Sep 6;372(9641):807-16. doi: 10.1016/S0140-6736(08)61170-8. Epub 2008 Aug 29.</citation>
    <PMID>18757088</PMID>
  </reference>
  <reference>
    <citation>Borer JS, Fox K, Jaillon P, Lerebours G; Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003 Feb 18;107(6):817-23.</citation>
    <PMID>12591750</PMID>
  </reference>
  <reference>
    <citation>Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005 Dec;26(23):2529-36. Epub 2005 Oct 7.</citation>
    <PMID>16214830</PMID>
  </reference>
  <reference>
    <citation>Kaneko A, Tachibana M. A voltage-clamp analysis of membrane currents in solitary bipolar cells dissociated from Carassius auratus. J Physiol. 1985 Jan;358:131-52.</citation>
    <PMID>2580078</PMID>
  </reference>
  <reference>
    <citation>Demontis GC, Longoni B, Barcaro U, Cervetto L. Properties and functional roles of hyperpolarization-gated currents in guinea-pig retinal rods. J Physiol. 1999 Mar 15;515 ( Pt 3):813-28.</citation>
    <PMID>10066907</PMID>
  </reference>
  <reference>
    <citation>Satoh TO, Yamada M. A bradycardiac agent ZD7288 blocks the hyperpolarization-activated current (I(h)) in retinal rod photoreceptors. Neuropharmacology. 2000 Apr 27;39(7):1284-91.</citation>
    <PMID>10760370</PMID>
  </reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <last_update_submitted>June 11, 2012</last_update_submitted>
  <last_update_submitted_qc>June 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2012</last_update_posted>
  <responsible_party>
    <name_title>Sebastian Majewski, MD</name_title>
    <organization>Medical University of Lodz, Department of Pneumonology and Allergy</organization>
  </responsible_party>
  <keyword>asthma, chronic obstructive pulmonary disease, COPD, ivabradine, heart rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

